Posted by Michael Wonder on 29 Nov 2021
Mayne Pharma and Mithra announce TGA approval of Nextstellis oral contraceptive
29 November 2021 - Mayne Pharma and Mithra Pharmaceuticals are very pleased to announce the TGA has approved the novel combined oral contraceptive Nextstellis (14.2 mg of estetrol and 3 mg drospirenone tablets).
Mayne Pharma anticipates the commercial launch of Nextstellis by mid 2022 supported by health care professional market education from January 2022.
